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We performed a systematic review of studies that investigated the effect of abnormalities of the tumour suppressor gene p53 upon
prognosis in patients with colorectal cancer. The methods used to assess p53 status were immunohistochemistry (IHC), indicating
abnormal accumulation of p53, and sequence analysis, indicating presence of p53 mutations (mut). We identified 168 reports, with
241 comparisons of relevant end points and survival data on 18766 patients. We found evidence of both publication bias and
heterogeneity of results. Our analysis was hampered by variability in both the assessment of p53 status and the reporting of results.
We used a trim and fill method to correct for publication bias and minimised heterogeneity by using well-defined clinical subgroups
for the assessment of outcomes. Overall, patients with abnormal p53 were at increased risk of death: relative risk (RR) with IHC 1.32
(95% confidence interval (c.i.) 1.23–1.42) and with mutation analysis 1.31 (95% c.i. 1.19–1.45). The adverse impact of abnormal p53
was greater in patients with lower baseline risk of dying: good prognosis RR (mut) 1.63 (95% c.i. 1.40–1.90) and poor prognosis RR
(mut) 1.04 (95% c.i. 0.91–1.19). We found no effect of abnormal p53 on outcome in patients treated with chemotherapy. Abnormal
p53 was associated with failure of response to radiotherapy in patients with rectal cancer: RR (mut) 1.49 (95% c.i. 1.25–1.77).
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P53 is abnormal in more than 50% of human tumours (Vogelstein,
1990; Hollstein et al, 1991). Despite over 20 years of investigations,
we do not know whether or not this finding is of any clinical
significance. The primary function of the p53 protein is as a
tumour suppressor. It can induce temporary cell cycle arrest,
permitting time for repair of any DNA damage; it can induce
apoptosis; and it can impose a permanent block on any future
attempts at cell division (Lane et al, 1995; Hall and Lane, 1997;
Balint and Vousden, 2001). In short, it can instruct cells to shape
up, ship out, or forever cease dividing. Loss of these crucial
functions could, in patients whose tumours contain abnormal p53,
result in poorer outcomes than in patients whose tumours have
fully functional p53. We can draw a clear distinction between p53
as an adverse prognostic factor (patients with abnormal p53 are
more likely to die than patients with normal p53) and p53 as a
predictive factor (patients with abnormal p53 are less likely to
respond to a given treatment, say 5-fluorouracil-based chemother-
apy, than patients whose p53 is normal). Prognostic factors tell us
something of a tumour’s intrinsic biological potential, and
predictive factors tell us whether or not a particular treatment is
likely to work or not.
The literature on p53 is vast. There are over 26000 citations on
Embase and more than 32000 on Medline (July 2004). Despite this
wealth of knowledge, there is no clear evidence that testing for
abnormalities of p53 provides information that is useful in either a
prognostic or a predictive sense. Studies on the prognostic value of
p53 abnormalities are, for the reasons summarised in Table 1,
extremely heterogeneous. Given this variety, it is not surprising
that no clear answers have emerged. In this review, we have
attempted to cut through some of these difficulties: we have used a
systematic approach to the identification and analysis of studies
and have confined our attentions to one tumour type, colorectal
cancer. We have tried to define homogeneous groups of patients
who address clinically important issues. We have attempted to
answer a simple question: are patients whose tumours contain
abnormal p53 more likely to die than patients whose p53 is
normal?
MATERIAL AND METHODS
We performed a systematic search of the literature using both
Embase (from 1988) and Medline (from 1966) up to July 2004. We
used the following search strategy (simplified):
1. (p53 and prog$).ab,sh,hw,ti,kw.
2. (p53 and pred$).ab,sh,hw,ti,kw.
3. combine 1 and 2
4. limit 3 to human
5. cancer.mp. [mp¼ti, ab, rw, sh] or tumor.mp. [mp¼ti, ab, rw,
sh] or tumour.mp. [mp¼ti, ab, rw, sh] or neoplasm.mp.
[mp¼ti, ab, rw, sh]
6. (colon or colorectal or rectum or rectal).mp. [mp¼ti, ab, rw,
sh]
7. combine 5 and 6
8. limit 7 to human
9. combine 8 and 4
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sThis strategy yielded a total of 757 Embase citations and 954
Medline citations. These two sets were amalgamated, with
duplicates discarded, and this produced a final set of 1169
potentially relevant citations. The titles and abstracts of these
citations were carefully scrutinised and a study was considered
eligible for the systematic review if it satisfied the following
criteria:
Full publication with details of methods available.
Used human material.
Contained data on assessment of p53 status.
Contained outcome data for patients with colorectal cancer
according to p53 status (outcomes were overall survival; tumour
response; development of metastatic disease).
In studies reporting survival, there was a minimum of 6 months
follow-up.
Sufficient detail provided to permit extraction of data for
numerical analysis.
A uniform protocol was used to extract data from the full
publication. Events were negatively framed (death, no response,
metastatic disease). The clinical context was defined as follows:
local preoperative treatment for rectal cancer, postsurgical
adjuvant and advanced disease (local and/or metastatic). The
primary tumour site was coded as: colon, rectum and colorectal,
not otherwise specified. The methods used to assess p53 status
were classified as either mutation analysis or immunohistochem-
istry (IHC). The analyses of mutations used single-strand
conformational polymorphism or polymerase chain reaction with
sequencing. The number of exons analysed was recorded for each
such study. For the immunohistochemical studies, we recorded
antibody used, type of specimen (fresh fixed, fresh unfixed, fixed
archival) and the criterion used to define abnormal accumulation
of p53.
Survival data were extracted using scanned images of published
curves. The number of survivors at the maximal reliable time point
was estimated using measurements from a planimetric software
program, Mouseyes (Taylor, 2001). The maximum reliable time
point was determined by inspection of the survival curves and was
never more than twice the median survival time: values ranged
from 2 to 14 years with a median of 5 years.
The data were analysed using Stata software version 7 (Stata
Corporation, College Station, TX, USA). Unless otherwise speci-
fied, all analyses were performed using the random effects method
(DerSimonian and Laird, 1986). We estimated absolute rate
differences and relative risks (RR) for each study. We have used
95% confidence intervals (c.i.) throughout. Heterogeneity was
assessed using the standard approach based on a w
2 distribution
for the parameter Q, the measure of heterogeneity in a random
effects model (DerSimonian and Laird, 1986). We anticipated that
heterogeneity would cause problems with the legitimate pooling of
results. We were also concerned that treatment might act as hidden
confounder and so, in advance, specified that we would investigate
the part played by p53 in influencing the following clinical
outcomes:
Response to radiotherapy (with or without chemotherapy) in
patients with rectal cancer.
Survival, and response to treatment, in patients with advanced
disease.
Survival in patients not treated with chemotherapy after curative
surgical treatment.
Survival in patients treated with adjuvant chemotherapy after
curative surgical treatment.
Survival in patients for whom there was no information as to
whether or not they had been treated with chemotherapy after
curative surgical treatment.
Development of metastatic disease in patients with apparently
localised disease.
Publication bias was assessed using the methods proposed by
Begg (Begg and Mazumdar, 1994) and by Egger (Egger et al, 1997).
The trim and fill technique (Duval and Tweedie, 2000) was used to
investigate the impact of any bias that was suggested. We
performed limited regression analyses using the method suggested
by Thompson and Sharp (1999).
We assessed any bias in data extraction by carrying out
regression analysis of our estimate of RR against the RR or hazard
ratio (HR) reported by the original investigators, where available.
Any systematic bias would produce an intercept value greater than
zero.
RESULTS
The search strategy identified 227 relevant papers and abstracts.
Since some papers reported data on more than one end point, we
were able to identify 287 comparisons. The reports included data
from a total of 33648 patients. Once we had eliminated duplicate
publication of the same data, there were 168 papers, with 241
comparisons, left. These studies published survival data on 18766
patients, response data on 1514 patients and, for 1066 patients,
data on the effect of abnormal p53 upon the development of
metastatic disease were available.
In 61 studies, we were able to compare the extracted RR with the
RR or HR reported by the authors. There was good agreement
(Spearman’s correlation coefficient 0.70, Po0.0001). The intercept
of the regression line on the Y-axis (RR) was 0.01.
The overall effects of abnormal p53 upon survival are shown in
Figures 1–4. The majority of the immunohistochemical studies
used either DO-7 or Pab-1801 as the antibody for identifying
abnormal accumulation of p53 and so results for these antibodies
are shown separately. Table 2 shows the accompanying numerical
Table 1 Sources of heterogeneity in studies assessing the value of abnormal p53 as a predictive or prognostic marker
Different tumour types, different histological grades, different clinical stages
Different tissue: primary vs metastases
Different treatments
Different ethnic groups
Different socioeconomic groups (smoking, alcohol)
Different experimental designs: retrospective case reports)prospective studies nested within randomised trials
Different sample types: fresh–frozen, fresh–fixed, archival
Different assay techniques: IHC; mutation analysis
Different criteria for discriminating between normal and abnormal p53 (cutoff levels)
Different effects of different abnormalities of p53
Different effects on different components of the p53 pathway (no molecule is an island unto itself)
IHC¼immunohistochemistry.
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Poller (1997)
Pereira (1997)
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Mulder (1995)
Morrin (1994)
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Manne (1998)
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Lenz (1998)
Leahy (1996)
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Lanza (1996)
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Jingwei (1998)
Hirvikoski (1999)
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Edler (2000)
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Caldes (1998)
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Bhatavdekar (1997)
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Bell (1993)
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Allegra (2002)
Allegra (2003)
Ahnen (1998)
Adrover (1999)
Figure 1 Forest plot for all studies, with survival as outcome, using IHC to define p53 status. LogRR – log relative risk, values 41.0 indicate that abnormal
p53 is associated with increased hazard, that is, lower survival. Each study is shown with its 95% c.i. The size of the square symbol is proportional to the
weight assigned to the study in the pooled estimate using a random effects model.
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sdata. As anticipated, these analyses, with the exception of IHC
using Pab-1801, show considerable heterogeneity and so we
performed a series of more restricted analyses. We found no
evidence for any relationship between the criterion used to define
‘positive’ by IHC and outcome. For example, using the DO-7
antibody, and with survival as outcome, the absolute rate
Survival–all patients, mutation analysis
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Figure 2 Forest plot for all studies, with survival as outcome, using analysis of sequence data to define p53 status.
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sdifference was 13.4% (95% c.i. 2.4–24.5%) when the criterion was
set at 41% cells positive, and 13.5% (95% c.i. 6.9% to 20.1%) when
a cutoff value of 410% positivity was used.
Table 3 shows analyses by tumour site and, in addition, shows
data on publication bias and its likely effect upon the estimates of
effect. There is clear evidence of publication bias and, as expected,
Survival–immunohistochemical analysis using DO-7
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Figure 3 Forest plot for all studies, with survival as outcome, using IHC with the DO-7 antibody to define p53 status.
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Figure 4 Forest plot for all studies, with survival as outcome, using IHC with the Pab-1801 antibody to define p53 status.
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sits effect is to exaggerate any estimate of the adverse effect of p53
upon survival. The estimates of RR are inflated by 0.20, which
corresponds, in this population of patients, to overestimating the
absolute rate difference by about 10%.
Figure 5A and B are funnel plots illustrating the trim and fill
approach to publication bias (Duval and Tweedie, 2000). The
round circles show individual studies on a plot of estimates of the
log risk ratio vs its standard error. The circles with squares around
them, 30 in number, in Figure 5B indicate dummy studies invented
by the trim and fill method to counteract bias. Points lying above
zero on the Y-axis are positive studies, and points lying below are
negative studies. The further to the right a point lies, the lower the
statistical power of the study it represents. If publication bias did
not apply, all points would lie symmetrically about the central
measure of effect, the horizontal line which, in this case, is just
above zero. The plot clearly shows that small negative studies are
under-represented (fewer circles towards the bottom right of the
graph in Figure 5A) and the use of the dummy studies to
compensate for this deficiency.
The data in Table 4 are from analyses restricted to clinically
useful categories. This approach considerably reduces heteroge-
neity, or at least the statistical estimate thereof, and also reduces
the impact of any publication bias.
Using regression analysis, we investigated the possibility that
treatment with chemotherapy might confound estimates of effect
in studies of patients treated by curative surgical resection. We
used the percentage of patients in each study known to have been
treated with chemotherapy as the predictive variable. We could
find no significant effect: in studies using IHC, the regression
coefficient was 0.0023 ( 0.0031 to þ0.0077; P¼0.41) and in
studies using analysis of mutations, the coefficient was 0.0012
( 0.0031 to þ0.0056; P¼0.577). These findings are consistent
with the results in Table 4, which show no discernible effect of
chemotherapy upon the estimate of RR.
We also used metaregression to assess whether baseline risk,
defined as the risk of death in patients with normal p53, had any
influence upon the effect of abnormal p53 on survival. Baseline
risk had a marked influence on the adverse effect of abnormal p53
(Po0.0001). This applied whether p53 status had been assessed by
IHC or by mutational analysis. For every 10% rise in baseline risk
of death, the absolute rate difference associated with abnormal p53
decreased by 6% (95% c.i. 4–8%; Po0.0001) Figure 6. This effect
persisted after adjustment for the percentage of patients in each
study receiving chemotherapy.
The median baseline risk was 0.35. We used this value to divide
groups of patients into those with good prognosis (risk of death
o35%) and those with poor prognosis (risk of death 435%).
Table 5 shows the effect of abnormal p53 upon outcome for
patients treated by curative surgery according to baseline risk. The
adverse effect of p53 upon outcome is greater in those patients
whose underlying prognosis is better.
DISCUSSION
This review epitomises the difficulties and pitfalls encountered in
systematic reviews of observational studies. We found evidence for
significant publication bias and, in the pooled analyses of survival,
heterogeneity erodes the validity of the estimates of overall effect.
Figures 1–4 are best interpreted as a convenient means of showing
the pattern of results. They do not provide any precise estimate of
overall effect.
The presence of publication bias (Tables 3 and 4) means that,
according to the results of the compensatory trim and fill method
(Duval and Tweedie, 2000), unadjusted estimates of the adverse
effect of abnormal p53 should be scaled downwards: by about 0.22
for RR and by around 10% for absolute rate difference. However,
Table 2 Summary data on all comparisons with survival as the end point
Group Rate difference (95% c.i.) P het. P sig. RR (95% c.i.) P het. P sig. Events Total
IHC
All 0.13 (0.10–0.16) o0.0001 o0.0001 1.32 (1.23–1.42) o0.0001 o0.0001 5087 12257
DO-7 0.10 (0.05–1.14) o0.0001 o0.0001 1.24 (1.12–1.37) o0.0001 o0.0001 2566 6436
Pab-1801 0.16 (0.09–0.23) 0.05 o0.0001 1.40 (1.18–1.66) 0.132 o0.0001 511 1281
Others 0.15 (0.10–0.21) o0.0001 o0.0001 1.43 (1.25–1.63) o0.0001 o0.0001 2010 4540
Mutations 0.12 (0.08–0.17) o0.0001 o0.0001 1.31 (1.19–1.45) o0.0001 o0.0001 3128 6645
IHC¼immunohistochemical detection of accumulation of p53; DO-7¼studies using the DO-7 antibody; Pab-1801¼studies using the antibody Pab-1801; others¼all other
IHC studies; mutations¼studies in which p53 mutations were identified using sequencing; RR¼relative risk; c.i.¼confidence interval; P het.¼the P value, derived from the Q
statistic, for heterogeneity/homogeneity. The lower the P-value, the less likely it is that the studies in the analysis are homogeneous: low P-values indicate heterogeneity.
P sig.¼the P-value for the observed effect; events¼deaths; total¼total number of patients in each analysis.
Table 3 Summary data on survival by method and site
Site Method Studies RR Sig Het Begg Eggers Fill T&F(R) T&F(F) T&F het
Rectum IHC 16 1.29 (1.00–1.66) 0.048 o0.0001 0.685 0.295 1 1.22 (0.94–1.59) P¼0.135 1.16 (1.03–1.30) P¼0.014 o0.0001
Mut 7 1.28 (1.06–1.54) 0.011 0.004 0.368 0.063 2 1.32 (0.89–1.94) P¼0.165 1.19 (0.99–1.43) P¼0.058 0.001
Colon IHC 9 1.28 (1.01–1.62) 0.042 0.001 0.076 0.097 2 1.14 (0.89–1.48) P¼0.299 1.12 (1.00–1.27) P¼0.051 o0.0001
Mut 6 1.39 (1.12–1.74) 0.003 0.047 1.0 0.1 3 1.15 (0.93–1.42) P¼0.207 1.13 (1.04–1.24) P¼0.007 0.001
Colorectal IHC 64 1.34 (1.24–1.46) o0.0001 o0.0001 0.007 o0.0001 24 1.12 (1.03–1.22) P¼0.01 1.06 (1.03–1.09) Po0.0001 o0.0001
Mut 30 1.28 (1.13–1.44) o0.0001 o0.0001 0.052 o0.0001 11 1.06 (0.94–1.2) P¼0.329 1.02 (0.97–1.08) P¼0.414 o0.0001
IHC¼immunohistochemistry; Mut¼analysis of mutations using sequencing; studies¼number of included studies; RR¼relative risk, with 95% c.i. in brackets; Sig¼P-value for
the observed effect; Het¼P-value for heterogeneity; Begg¼P-value for publication bias calculated using Begg’s method; Egger¼P-value for publication bias calculated used
Egger’s method; fill¼number of studies added by trim and fill method; T&F(R)¼relative risk (and 95% c.i.) of trimmed and filled analysis calculated using assumption of random
effects; T&F(F)¼relative risk (and 95% c.i.) calculated using assumption of fixed effects; T&F het¼P-value for homogeneity/heterogeneity calculated for trimmed and filled
analysis.
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Figure 5 logRR – log relative risk; s.e. – standard error (A) Funnel plot of data on survival in studies using IHC. As discussed in the text, there is evidence
of publication bias – asymmetry due to lack of negative studies with high standard error and low statistical power. (B) Funnel plot of the same group of
studies after trimming and filling. The dummy studies are indicated by circles within squares, and the genuine studies, as in (A), by circles.
Table 4 Analysis of studies dealing with clinically relevant subgroups
Comparison Method N RR Sig Het Begg Eggers T&F
Rectal cancer
Response – XRT/chemo-RT
IHC 13 1.15 (0.88–1.52) 0.31 0.048 0.502 0.019 No change
Mut 6 1.49 (1.25–1.77) o0.0001 0.752 0.707 0.04 No change
Advanced disease
Response – chemo
IHC 9 1.11 (0.93–1.31) 0.235 0.048 0.348 0.113 1.02 (0.85–1.22) P¼0.862
Mut 2 0.65 (0.32–1.32) 0.231 0.144 N/A N/A N/A
Advanced disease
Survival
IHC 7 1.09 (0.96–1.23) 0.186 0.065 0.138 0.236 1.04 (0.91–1.18) P¼0.572
Mut 8 0.97 (0.81–1.16) 0.736 0.007 1.00 0.665 0.92 (0.76–1.11) P¼0.373
Postsurgical: no adjuvant chemo
Survival
IHC 11 1.28 (1.10–1.49) 0.002 0.067 0.119 0.072 No change
Mut 4 1.67 (1.35–2.03) o0.0001 0.471 0.089 0.089 No change
Postsurgical: adjuvant chemo
Survival
IHC 6 1.66 (1.16–2.79) 0.005 0.001 0.26 0.054 1.26 (0.84–1.91) P¼0.264
Mut 3 1.60 (1.27–2.02) o0.0001 0.649 0.296 0.239 No change
Postsurgical: chemo unknown
Survival
IHC 40 1.53 (1.36–1.73) o0.0001 o0.0001 0.002 o0.0001 1.26 (1.11–1.43) Po0.0001
Mut 15 1.60 (1.30–1.94) o0.0001 0.002 0.048 0.001 1.20 (0.98–1.48) P¼0.073
Development of metastases IHC 8 1.09 (0.78–1.53) 0.51 0.043 0.06 0.02 0.92 (0.61–1.39) P¼0.682
Mut 2 1.67 (1.21–2.30) 0.002 0.301 N/A N/A N/A
IHC¼immunohistochemistry; Mut¼analysis of mutations using sequencing; N¼number of studies included in analysis; RR¼relative risk, with 95% c.i. in brackets; sig¼P value
for the observed effect; het¼P-value for heterogeneity; Begg¼P-value for publication bias calculated using Begg’s method; Egger¼P-value for publication bias calculated using
Egger’s method; T&F¼result of trimmed and filled analysis, using assumption of random effects; N/A¼not applicable.
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bias (Sterne and Egger, 2000) and so the figures, 0.22 and 10%,
should be regarded as maximal estimates of the effect of
publication bias. There is no clear evidence that the adverse effect
of abnormal p53 upon outcome depends upon the location of the
primary tumour (Table 3). The adjusted estimates of RR are
between 1.16 and 1.19 for rectal tumours and around 1.13 for
colonic tumours. This issue is distinct from the difference in the
Postsurgical patients IHC survival
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Figure 6 Plot of the estimate of logRR (log relative risk) against baseline event rate in studies of patients operated upon for cure and whom p53 status
had been assessed using IHC. Baseline event rate, for each study, is defined as the proportion of deaths in patients with normal p53.
Table 5 Survival data from studies on patients who were considered to have had curative surgery
a
Group Method RR Rate difference Het. T&F RR
Good IHC 1.89 (1.63–2.19) Po0.0001 0.20 (0.16–0.25) Po0.0001 o0.0001 1.53 (1.30–1.80)
Mut 1.75 (1.51–2.02) Po0.0001 0.21 (0.16–0.26) Po0.0001 0.37 1.63 (1.40–1.90)
Bad IHC 1.13 (1.03–1.24) P¼0.009 0.06 (0.01–0.11) P¼0.015 o0.0001 No change
Mut 1.21 (1.07–1.37) P¼0.003 0.11 (0.03–0.18) P¼0.002 0.004 1.04 (0.91–1.19)
IHC¼immunohistochemistry; RR¼relative risk; Mut¼analysis of mutations using sequencing; RR and rate difference are shown together with 95% c.i. and the P-value for the
observed effect; Het¼the P-value for homogeneity/heterogeneity; T&F RR¼relative risk, and 95% c.i., after adjustment for publication bias using the trim and fill method
calculated using a random effects model.
aThe ‘good’ group involved studies in which patients with normal p53 had survival rates of over 65%; the ‘bad’ group involved studies in
which patients with normal p53 had survival rates less than 65%.
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srate of p53 abnormalities, which is commoner in left-sided, as
opposed to right-sided, tumours (Soong et al, 2000). In brief, p53
abnormalities may be commoner in rectal tumours, but the
adverse consequences of any p53 mutation are of similar
magnitude, regardless of whether the primary tumour is in the
colon or in the rectum.
By restricting the pooled analyses to well-defined clinical
questions (Table 4), we were able to decrease the apparent
heterogeneity and this, together with a reduction in publication
bias, means that we can draw some reasonably robust conclusions
from the data. Mutant p53, as detected by sequence analysis,
predicts treatment failure in patients with rectal cancer treated
with radiotherapy or chemoradiation (RR 1.49; c.i. 1.25–1.77).
Abnormal p53, as detected by IHC, has no predictive value in this
group of patients (RR 1.15; c.i. 0.88–1.52). Abnormalities in p53,
whether assessed immunohistochemically or by sequence analysis,
appear to be of no value in predicting response to chemotherapy
alone (Table 4). The effects of p53, and its abnormalities, on the
response of tumours to cytotoxic drugs, radiation, and chemo-
radiation are complex (Blandino et al, 1999; Bunz et al, 1999; El-
Deiry, 2003; Fei and El-Deiry, 2003; Gudkov and Komarova, 2003),
and it is, perhaps, unrealistic to expect a straightforward relation-
ship between any abnormality of p53 and the response to
treatment with chemotherapy. Another complicating factor is that
polymorphisms in wild-type p53, and its regulator, MDM2 (Bond
et al, 2004), may also affect response to treatment (Sullivan et al,
2004): in this respect, both ‘normal’ and ‘abnormal’ p53 are
heterogeneous entities.
The results from the studies on patients treated with potentially
curative surgery again suggest that abnormalities of p53 may have
no significant impact upon the response of colorectal cancer to
chemotherapy. This is suggested both by the data in Table 4 and by
regression analysis showing that the percentage of patients within
a study who were treated with adjuvant chemotherapy had no
influence upon RR. Unfortunately, due to the conduct and
reporting of the studies included in this systematic review, it is
not possible to pursue this argument further.
The evidence on the effect of the p53 status of the primary
tumour upon the likelihood of metastatic disease is conflicting.
The immunohistochemical data suggest no effect (RR 0.92; c.i.
0.61–1.39), whereas the more limited data using analysis of
mutations suggest that abnormal p53 may significantly increase
the risk of the development of metastatic disease (RR 1.67; c.i.
1.21–2.30). This is clearly an area that warrants further investi-
gation.
The most important conclusion to emerge from this review is
the recognition that, in patients treated with curative surgery, the
baseline risk of death is an important factor in determining the
magnitude of the adverse effect on survival associated with
abnormal p53 (Table 5 and Figure 6). Abnormal p53 had
more of an impact on survival in patients whose underlying
prognosis was better. This suggests that abnormalities in p53
may have an independently adverse impact upon prognosis.
This question is best addressed prospectively and could be
incorporated into the design of clinical trials. Adjusted analyses,
with p53 status as a separate variable, would indicate whether
abnormalities in p53 have an adverse effect over and above that
associated with known prognostic factors, such as clinicopatholo-
gical stage.
Only one previous review (Petersen et al, 2001) has addressed
the question of whether or not abnormalities of p53 affect outcome
in patients with colorectal cancer. Their review included 28 studies,
involving 4416 patients. Their results suggested that, overall,
abnormal p53 had an adverse effect on survival, but that this effect
was by no means consistent. They concluded that: ‘p53 remains an
investigational parameter’. Our own review takes things a little
further, but not as far as the investment of resources in
investigating the prognostic value of p53 in colorectal cancer
should have enabled us to go. It is salutary to realise that,
worldwide, we have studied over 18000 patients and spent, at a
conservative estimate, over d6.5 million on investigating abnormal
p53 in colorectal cancer; yet we have found out very little that we
can put to clinical use.
One reason for this is a certain naı ¨vete ´ concerning techniques
for assessing abnormalities in p53. Positive IHC does not
necessarily imply that p53 is functionally inactive nor does the
absence of a demonstrable mutation mean that p53 is fully active.
The use of IHC to identify mutant p53 is based on the assumption
that abnormal p53 cannot act as a transcription factor. It cannot,
therefore, switch on its own, MDM2 mediated, destruction. And so
it accumulates. This may be an oversimplification. Accumulation
of p53, as detected immunohistochemically, may not inevitably
imply the presence of p53 that, through mutation, is transcrip-
tionally inactive. Wild-type p53 might accumulate if there is
amplification or overexpression of HDMX proteins (Ramos et al,
2001); if p53 is denied access to the nucleus (O’Brate and
Giannakakou, 2003); and if p73 isoforms impair the transcriptional
activity of wild-type p53 (Concin et al, 2004). All mutations in p53
have been treated as if they were of equal prognostic significance:
an assumption that should not be taken for granted. Mutations in
p53 can have a variety of effects and these include gain of function
as well as loss of function. Loss of functional p53 implies an
inability to undergo apoptosis or cell cycle arrest, which may, in
turn, lead to genomic instability. Dominant-negative mutations
will suppress the functional activity of any wild-type p53 that is
present, leading to loss of normal protective mechanisms. Some
p53 mutations cause gain of function that is independent
of any complex formation with wild-type p53 and is associated
with selective proliferative advantage (Gurova et al, 2003;
Scian et al, 2004). There is good evidence that different mutations
in p53 have different effects upon the sensitivity of tumours to
treatment (Blandino et al, 1999; Dridi et al, 2003; Klumb et al,
2003). P53 has a pivotal role in cellular husbandry and the p53
protein does not operate in isolation. The actions of p53 are
influenced by other members of the p53 pathway and a
straightforward ‘normal is good – all mutation is bad’ argument
is unlikely to apply.
There is a clear distinction between an observation that is
biologically interesting and a test that is clinically useful. The
former simply implies some degree of association; the latter
requires a tight relationship between the biological finding and the
clinical outcome. The positive predictive value (PPV) is a useful
metric for assessing a prognostic or predictive factor. It is easily
computed and can be expressed straightforwardly in words: ‘what
proportion of subjects with a positive test result experiences the
outcome of interest?’. Our results suggest that, with current
methods of assessment, p53 status is a poor guide to outcome
(prognosis) or response to treatment (prediction). The PPV’s
derived from our analysis are typically around 0.5, no better than
the toss of a coin.
The problems with the design and interpretation of studies
dealing with the assessment of prognostic factors have been well
rehearsed (Altman and Lyman, 1998; Altman, 2001; Deeks et al,
2003; Riley et al, 2003a,b; Riley et al, 2004). During the progress of
this review, we encountered most of them. The problems listed in
Table 1 remain with us. Future studies on p53 as a prognostic
factor should include data on subgroups defined by clinicopatho-
logical stage, by site of tumour, and by treatment. We also need a
more standardised approach to the investigation of p53 status.
There is, to judge by usage, no consensus on any optimal method
for the use of IHC to detect abnormal accumulation of p53; nor is
there any apparent agreement on how best to identify mutations in
the 11 exons of the p53 gene. Given that mutation and
accumulation, as detected by IHC, may be telling us different
things (Bazan et al, 2002), it would be sensible if future studies
combined both methods of assessment. Until procedures and
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sapproaches to the investigation of p53 status are standardised,
there can be no real progress:
Dix millions d’ignorances, ne font pas un savoir (Ten million
errors do not leave us any the wiser; Hippolyte Taine, 1823–
1898).
In the meantime, we can conclude with some degree of
confidence that:
In patients with better underlying prognosis, that is, survival
rates of 465% after surgery, abnormal p53 has an adverse effect
on outcome.
Abnormal p53 does not affect the outcome in patients treated
with 5FU-based chemotherapy.
Rectal tumours containing proven mutations in p53 are less
likely to respond to radiation, or chemoradiation, than rectal
cancers without evidence of mutant p53.
To the question: are patients whose tumours contain abnormal
p53 more likely to die than patients whose p53 is normal?, we can
only answer: sometimes.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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